While Alexion Pharmaceuticals’ blockbuster drug Soliris netted more than $3 billion for the company last year, the drug could face some stiff competition in Apellis Pharmaceutical’s new drug, APL-2, Bloomberg Opinion Columnist Max Nisen writes.
According to Nisen, Apellis Pharmaceuticals recently published a head-to-head trial of APL-2 and Soliris for the treatment of a rare form of anemia. The study suggests APL-2 was the clear victor over Soliris.
“If Apellis can get regulatory approval and demonstrate efficacy in other diseases, it could have a blockbuster of its own on its hands,” Nisen writes.
To read the full piece, click here.